
Patients with corrected presbyopia used larger fonts, held smartphones farther away, and read more slowly, suggesting 40-cm testing may miss device demands.
Potential presbyopia treatment coming
Learn more about the recent new drug application (NDA) Allergan submitted for its investigational eyedrop to treat presbyopia. Optometry Times® Editor in Chief Gretchyn Bailey, NCLC, FAAO, chats with Michael Robinson, MD, vice president, global therapeutic area head of ophthalmology at Allergan, to get details on when ODs could discuss a potential presbyopia treatment with their patients.





